Metastatic Melanoma: Updates from ASCO 2017 (ACPE)

Annual meetings of large, national, professional societies offer an opportunity for healthcare professionals to get a first glimpse at study results that have the potential to impact practice as provide a forum for an exchange of ideas and practices between thought leaders and less distinguished practitioners. ASCO 2017 is no exception. Nevertheless, as with every meeting, many professionals from both the community and health-system settings alike will be unable to attend the conference for a variety of reasons, justifying the creation of educational programming that summarize the major findings presented at the meeting.

Melanoma is a tumor of the melanocytes whose tissue of origin is primarily the skin, although it may also develop occasionally in the: gastrointestinal, genitourinary, or respiratory tracts; ocular or mucosal tissue; or meninges. It is subcategorized into superficial spreading melanoma (70% of cases), nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma. Risk factors include a positive personal or family history of melanoma, genetic predisposition, and exposure to ultraviolet light. Diagnosis is made by excisional, incisional, or punch skin biopsy while imaging or indirect ophthalmoscopy may be employed to diagnose uveal or choroidal melanoma. The seventh most common cancer in the U.S., it has an annual incidence of over 76,000.

Credit Designation:

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.00 hours of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.